Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 10:12:702726.
doi: 10.3389/fimmu.2021.702726. eCollection 2021.

Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment

Affiliations
Review

Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment

Ellen N Scott et al. Front Immunol. .

Abstract

Regulatory T cells (Tregs) are key immunosuppressive cells that promote tumor growth by hindering the effector immune response. Tregs utilize multiple suppressive mechanisms to inhibit pro-inflammatory responses within the tumor microenvironment (TME) by inhibition of effector function and immune cell migration, secretion of inhibitory cytokines, metabolic disruption and promotion of metastasis. In turn, Tregs are being targeted in the clinic either alone or in combination with other immunotherapies, in efforts to overcome the immunosuppressive TME and increase anti-tumor effects. However, it is now appreciated that Tregs not only suppress cells intratumorally via direct engagement, but also serve as key interactors in the peritumor, stroma, vasculature and lymphatics to limit anti-tumor immune responses prior to tumor infiltration. We will review the suppressive mechanisms that Tregs utilize to alter immune and non-immune cells outside and within the TME and discuss how these mechanisms collectively allow Tregs to create and promote a physical and biological barrier, resulting in an immune-excluded or limited tumor microenvironment.

Keywords: cancer; immune infiltration; regulatory T cells (Treg); stroma; tumor microenvironment; vasculature.

PubMed Disclaimer

Conflict of interest statement

DV: cofounder and stockholder – Novasenta, Tizona and Trishula; stockholder – Oncorus, Werewolf and Apeximmune; patents licensed and royalties - Astellas, BMS; scientific advisory board member - Tizona, Werewolf, F-Star, Bicara, Apeximmune; consultant - Astellas, BMS, Incyte, Almirall, G1 Therapeutics; research funding – Novasenta, BMS and Astellas. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Overview of suppressive mechanisms used by Tregs to create barriers to immune infiltration into tumors. Panel (A) Within the TME, Tregs utilize inhibitory receptors (TIM-3, TIGIT, PD1, and LAG-3), inhibitory cytokines (TGFβ, IL-10, and IL-35), DC modulation (via CTLA-4 and LAG-3), and metabolic disruption (via CD39/CD73) to suppress the anti-tumor T cell response. (B) Treg-derived TGFβ induces cancer-associated fibroblast (CAF) development that increases extracellular matrix (ECM) production and deposition within the peritumoral space (stroma) to inhibit effector T cell migration. (C) Tregs block entry of effector T cells through preventing proper cytokine signals that promote high endothelial venule (HEV) formation as well as production of inhibitory IL-10 and VEGF to promote dysregulated angiogenesis. (D) In the periphery and secondary lymphoid organs (SLO), Tregs can modulate DC maturity and induce apoptosis to prevent proper effector T cell activation.

Similar articles

Cited by

References

    1. Hori S, Nomura T, Sakaguchi S. Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science (2003) 299:1057–61. 10.1126/science.1079490 - DOI - PubMed
    1. Xu T, Lu J, An H. The Relative Change in Regulatory T Cells / T Helper Lymphocytes Ratio as Parameter for Prediction of Therapy Efficacy in Metastatic Colorectal Cancer Patients. Oncotarget (2017) 8:109079–93. 10.18632/oncotarget.22606 - DOI - PMC - PubMed
    1. Solis-Castillo LA, Garcia-Romo GS, Diaz-Rodriguez A, Reyes-Hernandez D, Tellez-Rivera E, Rosales-Garcia VH, et al. . Tumor-Infiltrating Regulatory T Cells, CD8/Treg Ratio, and Cancer Stem Cells Are Correlated With Lymph Node Metastasis in Patients With Early Breast Cancer. Breast Cancer (2020) 27:837–49. 10.1007/s12282-020-01079-y - DOI - PubMed
    1. Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. Transient Regulatory T Cell Ablation Deters Oncogene-Driven Breast Cancer and Enhances Radiotherapy. J Exp Med (2013) 210:2435–66. 10.1084/jem.20130762 - DOI - PMC - PubMed
    1. Shimizu J, Yamazaki S, Sakaguchi S. Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity. J Immunol (1999) 163:5211–8. - PubMed

Publication types

LinkOut - more resources